WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

Firm News

Cydan, the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases, announced a new round of financing, raising a committed total of $34 million to advance the company's efforts to create new and innovative therapies for patients living with rare genetic diseases. The proceeds from this round of financing will fund Cydan II, Inc., continuing the mission of Cydan Development, Inc.

The WilmerHale team representing Cydan included Gary Schall, Stephanie Singer and Bill Caporizzo.

Read Cydan's press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.